个性化注射器为胰腺癌患者带来希望

IF 25.5 1区医学 Q1 IMMUNOLOGY

Immunity Pub Date : 2025-05-13 DOI:10.1016/j.immuni.2025.04.026

Longling Silvia Shui, Peter M.K. Westcott

引用次数: 0

摘要

胰腺癌传统上被认为对免疫治疗是难治性的。在《自然》杂志上发表的针对这种致命癌症的个性化mRNA疫苗的首次临床试验的后续研究中，Sethna等人报告了持久免疫的令人信服的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Personalized syringes offer hope for pancreatic cancer patients

Pancreatic cancer has traditionally been considered refractory to immunotherapy. In a follow-up to the first clinical trial of personalized mRNA vaccines against this deadly cancer, published in Nature, Sethna et al. report compelling evidence of long-lasting immunity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Immunity 医学-免疫学

CiteScore

49.40

自引率

2.20%

发文量

205

审稿时长

6 months

期刊介绍： Immunity is a publication that focuses on publishing significant advancements in research related to immunology. We encourage the submission of studies that offer groundbreaking immunological discoveries, whether at the molecular, cellular, or whole organism level. Topics of interest encompass a wide range, such as cancer, infectious diseases, neuroimmunology, autoimmune diseases, allergies, mucosal immunity, metabolic diseases, and homeostasis.